JSPR - Mergers and acquisitions

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders  Completed a concurrent PIPE financing raising $132 million in gross proceeds REDWOOD CITY, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update. "We are excited to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission o

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders  Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12 million upon signing and potential development and sales milestone payments Combined financing and transactions expected to fund combined company operations through the second half of 2028, including multiple clinical milestones REDWOOD CITY, Calif. and CAM